Cargando…

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

PURPOSE: PARP inhibitors (PARPi) have demonstrated efficacy in tumors with germline breast cancer susceptibility genes (gBRCA) 1 and 2 mutations, but further factors influencing response to PARPi are poorly understood. EXPERIMENTAL DESIGN: Breast cancer tumor tissue from patients with gBRCA1/2 mutat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blum, Joanne L., Laird, A. Douglas, Litton, Jennifer K., Rugo, Hope S., Ettl, Johannes, Hurvitz, Sara A., Martin, Miguel, Roché, Henri H., Lee, Kyung-Hun, Goodwin, Annabel, Chen, Ying, Lanzalone, Silvana, Chelliserry, Jijumon, Czibere, Akos, Hopkins, Julia F., Albacker, Lee A., Mina, Lida A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Precision Medicine and Imaging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365365/ https://www.ncbi.nlm.nih.gov/pubmed/35091441 http://dx.doi.org/10.1158/1078-0432.CCR-21-2080

Ejemplares similares

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study
por: Turner, Nicholas C., et al.
Publicado: (2023)

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
por: Hurvitz, Sara A., et al.
Publicado: (2019)

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
por: Rugo, Hope S, et al.
Publicado: (2019)

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
por: Litton, Jennifer K, et al.
Publicado: (2023)

Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
por: Liu, Xuan, et al.
Publicado: (2022)

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity
por: Litton, J. K., et al.
Publicado: (2017)

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
por: Bychkovsky, Brittany L., et al.
Publicado: (2022)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
por: Rugo, Hope S., et al.
Publicado: (2023)

Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
por: Belz, Jodi E., et al.
Publicado: (2017)

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
por: Polyanskaya, Elizaveta, et al.
Publicado: (2023)

Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay
por: Hu, Chunling, et al.
Publicado: (2022)

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
por: Savill, Kristin M Zimmerman, et al.
Publicado: (2023)

Timely Genetic Testing and Therapy Management in Patients With gBRCA-Mutated Metastatic Breast Cancer Receiving Talazoparib
por: Martinez, Ashley, et al.
Publicado: (2022)

A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
por: Gruber, Joshua J., et al.
Publicado: (2022)

Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study
por: Kotani, Haruru, et al.
Publicado: (2022)

Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
por: Zhang, Di, et al.
Publicado: (2021)

4260 Hollow, Degradable poly(N-Isopropylacrylamide) Derived Nanoparticles for the Delivery of Anti-Inflammatory Peptides for the Treatment and Prevention of Post-Traumatic Osteoarthritis
por: Deloney, Marcus A, et al.
Publicado: (2020)

4228 A latent class analysis of seriously ill adults with multiple chronic conditions receiving palliative care
por: Murali, Komal, et al.
Publicado: (2020)

4565 Sex-Specific Differences in the Genomic Landscape of Pediatric and Adult Glioblastoma
por: Ivanov, Nikolay A., et al.
Publicado: (2020)

74325 Vast sex-specific differences in transcriptional landscapes of pancreatic neuroendocrine tumors
por: Ivanov, Nikolay A., et al.
Publicado: (2021)

38081 A Whole Blood Signature of Neutrophil Expression and Adaptive Immune Downregulation Characterizes Sepsis Mortality
por: Giannini, H.M., et al.
Publicado: (2021)

4423 Impact of Gender on High On-Treatment Platelet Reactivity (HPR) and Major Adverse Cardiovascular Events (MACEs) in Caribbean Hispanic patients using Clopidogrel
por: Nunez Medina, Hector Jose, et al.
Publicado: (2020)

97856 Implementation of DPYD and UGT1A1 pharmacogenetic testing to guide chemotherapy dosing
por: Varughese, Lisa A., et al.
Publicado: (2021)

4199 A pilot randomized controlled trial of precision care for smoking cessation in the Southern Community Cohort Study
por: Senft, Nicole, et al.
Publicado: (2020)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

4146 Establishment of Screening Methods for G6DP Deficiency – Translational and Clinical Applications
por: Gomez, Christian, et al.
Publicado: (2020)

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature
por: Albarrán, Víctor, et al.
Publicado: (2023)

Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial—First progress report
por: Chori, Babangida S., et al.
Publicado: (2023)

Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer
por: Pietzak, Eugene J., et al.
Publicado: (2022)

308 Machine learning to predict genetic variation and cardiovascular risk in Hispanic patients with Systemic lupus erythematosus
por: González-Meléndez, Ariana, et al.
Publicado: (2023)

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
por: Schram, Alison M., et al.
Publicado: (2022)

Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer
por: Waks, Adrienne G., et al.
Publicado: (2022)

4429 Powering precision medicine research with the efficient construction of large diverse cohorts
por: Petukhova, Lynn, et al.
Publicado: (2020)

4058 Enhanced efficiency of large-scale clinical proteomic studies: when less is more
por: Thomas, Stefani, et al.
Publicado: (2020)

4513 European Ancestry as a Risk Factor for Atrial Fibrillation in Puerto Rican Hispanics
por: Gonzalez-Cordero, Ariel
Publicado: (2020)

4440 Enhanced radiation therapy using chlorin-e6 conjugated gold nanoparticles
por: Jenkins, Samir V, et al.
Publicado: (2020)

4089 Clinical Implementation of Monte Carlo Dose Calculation for Patient-Specific Radiotherapy Quality Assurance
por: Parenica, Holly Marie, et al.
Publicado: (2020)

4292 Epigenetic Age and Depressive Symptoms in African American Women with Cardiometabolic Conditions
por: Perez, Nicole B, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uunqojhfs4igur5a0gor9ea2b0